Gordan Lauc @ 2024 Biomarkers of Aging Conference

Gordan Lauc discusses the potential power of the human glycome to better understand and treat aging-related diseases and how IgG glycans are predictive biomarkers and modifiable functional effectors of age-related diseases.
Timestamps
[00:00:19] Glycans and their role in biology
[00:02:12] Genos' role in glycan R&D and its application in aging biology
[00:02:51] IgG gylcome composition is a biomarker of chronological and biological disease
[00:03:22] The GlycanAge clock of biological age and its application in disease
[00:05:51] IgG glycome may be a surrogate marker for lifespan and predictor of mortality
[00:07:17] Glycans predict cardiovascular events in a prospective study
[00:08:05] Disease-predicting glycan biomarkers can be changed through lifestyle and pharmacological interventions
[00:09:47] Accumulation of glycan data will reveal many previously invisible aspects of biology
Professor Gordan Lauc is the Director of the National Centre of Research Excellence in Personalised Healthcare and founder of Genos, Zagreb-based biotech company that is the global leader in high-throughput glycomics. In 2017 he initiated the launch of the Human Glycome project and is one of its two co-directors. By combining glycomic data with extensive genetic, epigenetic, biochemical, and physiological data on over 200,000 individual they are trying to understand the role of glycans in normal physiology and disease. His research led to the development of the GlycanAge test of biological age. Learn more about Genos here: genos-glyco.com/